argenx to Present at Upcoming Investor Conferences

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its participation in three upcoming investor conferences in September 2024:

• 2024 Wells Fargo Healthcare Conference: Fireside chat on September 4 at 1:30 p.m. ET in Boston, MA
• Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5 at 4:50 p.m. ET in New York, NY
• Baird 2024 Global Healthcare Conference: Fireside chat on September 10 at 9:40 a.m. ET in New York, NY

The company, which focuses on improving lives of people with severe autoimmune diseases, will have members of its management team present at these events. Additional information about these conferences will be available on the Investors section of the argenx website.

News Market Reaction

-0.16%

1 alert

-0.16% News Effect

On the day this news was published, ARGX declined 0.16%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

August 28, 2024

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:

• 2024 Wells Fargo Healthcare Conference. Fireside chat on Wednesday, September 4, 2024 at 1:30 p.m. ET in Boston, MA.
  
  
• Morgan Stanley 22^nd Annual Global Healthcare Conference. Fireside chat on Thursday, September 5, 2024 at 4:50 p.m. ET in New York, NY.
  
  
• Baird 2024 Global Healthcare Conference. Fireside chat on Tuesday, September 10, 2024 at 9:40 a.m. ET in New York, NY.
  
  

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

For further information, please contact:

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

Which investor conferences will argenx (ARGX) attend in September 2024?

argenx will attend three investor conferences in September 2024: the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.

When and where is argenx (ARGX) presenting at the Wells Fargo Healthcare Conference?

argenx will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 1:30 p.m. ET in Boston, MA.

What is the date and time for argenx's (ARGX) presentation at the Morgan Stanley Global Healthcare Conference?

argenx will have a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 4:50 p.m. ET in New York, NY.

Where can investors find more information about argenx's (ARGX) conference presentations?

Additional information about argenx's conference presentations will be available on the Investors section of the company's website at argenx.com/investors.